News | Wearable Sensors | September 09, 2015

SRI International Licenses DataSpeaks Software for Virtual Clinical Decision-Making

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data


DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information:,

Related Content

Cardiac Insight Partners With VivoSense for Cardiovascular Research
News | Wearable Sensors | November 09, 2018
Wearable cardiac biosensor developer Cardiac Insight Inc. has partnered with VivoSense, specializing in integration and...
Intelligent Planet Introduces ExMedicus Smartwatch
Technology | Wearable Sensors | November 02, 2018
Digital health company Planet Intelligent recently launched the ExMedicus Smartwatch, what it calls the world’s first...
iBeat Heart Watch Now Shipping
Technology | Wearable Sensors | August 15, 2018
iBeat recently announced the release and shipping of its iBeat Heart Watch. The heart and blood flow monitoring...
Caretaker Medical Wins CE Certification for Caretaker4 Wireless Vital Signs Monitor
News | Wearable Sensors | August 10, 2018
Caretaker Medical, creator of the Caretaker4 wireless CNIBP Vital signs monitor for continuous non-invasive blood...
Cash and Goal Setting Help Motivate Heart Patients to Take Healthy Steps
News | Wearable Sensors | June 13, 2018
The thought of losing up to $14 a week along with personalized goal setting may have motivated ischemic heart disease...
Medtronic to Discontinue SEEQ MCT Wearable Telemetry System
News | Wearable Sensors | May 23, 2018
Medtronic announced on May 23, 2018 that it will discontinue marketing for its SEEQ Mobile Cardiac Telemetry (MCT)...
Self-Applied Chest Patch Catches Atrial Fibrillation More Quickly Than Usual Care
News | Wearable Sensors | March 19, 2018
For people at heightened risk for atrial fibrillation (AFib), a common heart rhythm disorder that also carries a high...
Videos | Wearable Sensors | January 29, 2018
Take a video tour of some of the medical devices designed to improve patient care, improve patient engagement and inc
FDA Issues Safety Communication on Zoll LifeVest 4000 Wearable Cardioverter Defibrillator
News | Wearable Sensors | January 22, 2018
The U.S. Food and Drug Administration (FDA) announced last week it is providing information and recommendations...
Zoll and Myant Enter Strategic Research and Development Collaboration
News | Wearable Sensors | December 28, 2017
December 28, 2017 — Zoll Medical Corp.
Overlay Init